Literature DB >> 15731577

Cutaneous desmoplastic melanoma.

Klaus J Busam1.   

Abstract

Desmoplastic melanoma (DM) is a fibrosing variant of spindle cell melanoma. It most often presents as an indurated lesion in chronically sun-damaged skin. Due to the lack of characteristic clinical features, early detection is uncommon. At the time of excision, the tumors usually extend into the reticular dermis or deeper. DM is prone to misdiagnosis. It may simulate histologically sclerosing melanocytic nevi as well as various benign and malignant nonmelanocytic lesions. There is significant morphologic variability among tumors classified as DM. Desmoplasia may be prominent throughout the entire tumor ("pure" DM) or represent a portion of an otherwise nondesmoplastic melanoma ("combined" DM). Some tumors show neuroma-like features with prominent nerve involvement, in which case the term "desmoplastic neurotropic melanoma" is used. Immunophenotypically, DMs are usually strongly and homogeneously positive for S-100 protein but are often negative or only focally positive for melanocyte differentiation antigens such as tyrosinase, gp100, Melan-A, and microphthalmia transcription factor. DM differs from conventional melanoma in its clinical course. It is associated with a higher tendency for local recurrence, but metastases to regional lymph nodes are less common. Evidence is also emerging that for patients with thick melanomas, the presence of a paucicellular fibrosing tumor histology (pure DM) is a favorable prognostic factor for survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731577     DOI: 10.1097/01.pap.0000155071.86944.a6

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  23 in total

1.  Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas.

Authors:  Dale Han; Gang Han; Monica T Duque; Steven Morrison; Stanley P Leong; Mohammed Kashani-Sabet; John Vetto; Richard White; Schlomo Schneebaum; Barbara Pockaj; Nicola Mozzillo; Vernon K Sondak; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2020-06-10       Impact factor: 5.344

2.  Desmoplastic melanoma morphology on Thinprep: a report of two cases.

Authors:  Becky L Van Ells; James E Madory; Rana S Hoda
Journal:  Cytojournal       Date:  2007-09-19       Impact factor: 2.091

3.  [Histology of malignant tumors caused by UV light].

Authors:  M Megahed
Journal:  Hautarzt       Date:  2012-10       Impact factor: 0.751

4.  Desmoplastic melanoma with sarcomatoid dedifferentiation.

Authors:  Maija Kiuru; Gregory McDermott; Michael Berger; Allan C Halpern; Klaus J Busam
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

Review 5.  Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.

Authors:  Dale Han; Daniel C Thomas; Jonathan S Zager; Barbara Pockaj; Richard L White; Stanley Pl Leong
Journal:  World J Clin Oncol       Date:  2016-04-10

6.  Desmoplastic melanoma: is there a role for sentinel lymph node biopsy?

Authors:  Dale Han; Jonathan S Zager; Daohai Yu; Xiuhua Zhao; Brooke Walls; Suroosh S Marzban; Nikhil G Rao; Vernon K Sondak; Jane L Messina
Journal:  Ann Surg Oncol       Date:  2013-02-07       Impact factor: 5.344

7.  Mutational dichotomy in desmoplastic malignant melanoma corroborated by multigene panel analysis.

Authors:  Stephan W Jahn; Karl Kashofer; Iris Halbwedl; Gerlinde Winter; Laila El-Shabrawi-Caelen; Thomas Mentzel; Gerald Hoefler; Bernadette Liegl-Atzwanger
Journal:  Mod Pathol       Date:  2015-03-13       Impact factor: 7.842

8.  Functional RET G691S polymorphism in cutaneous malignant melanoma.

Authors:  N Narita; A Tanemura; R Murali; R A Scolyer; S Huang; T Arigami; S Yanagita; K K Chong; J F Thompson; D L Morton; D S Hoon
Journal:  Oncogene       Date:  2009-06-29       Impact factor: 9.867

9.  Desmoplastic melanoma: report of 5 cases.

Authors:  A M Manganoni; C Farisoglio; S Bassissi; D Braga; F Facchetti; M Ungari; P G Calzavara-Pinton
Journal:  Dermatol Res Pract       Date:  2009-11-30

10.  Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1.

Authors:  Nityanand Maddodi; Kumar M R Bhat; Sulochana Devi; Su-Chun Zhang; Vijayasaradhi Setaluri
Journal:  J Biol Chem       Date:  2009-10-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.